Recently, Perez-Ruiz et al. reported that the prophylactic blockade of TNFα before the start of combined checkpoint inhibition of PD-1 and CTLA-4 can prevent autoimmune adverse effects and additionally enhance anti-tumor treatment efficacy in mouse models [126]. This evidence concerns the gene PDCD1 and neoplasm.